Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Xentuzumab by Boehringer Ingelheim International for Non-Small Cell Lung Cancer: Likelihood of Approval
Xentuzumab is under clinical development by Boehringer Ingelheim International and currently in Phase I for Non-Small Cell Lung Cancer. According...